TA-CIN
Phase 1Biologic
TA-CIN is one of 47 biologic programs targeting Treatment. It is currently in Phase 1.
1
Indications
2
Total Trials
1
Active Trials
46
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
350 competitors in Treatment
#DrugCompanyPhaseTrials
1Biltricide
BayerPreclinical
Alfenta
Jazz PharmaceuticalsPreclinical
Niclocide
BayerPreclinical
Minipress
PfizerPreclinical
Theo-Dur
PfizerPreclinical
Hivid
CConrado Roberto Hoffmann Filho
Preclinical
Aurlumyn
BBTG International Inc.
Preclinical
Lotemax
PPharmos
Preclinical
Norpramin
VValidus Pharmaceuticals
Preclinical
Barhemsys
Tibotec Pharmaceuticals, IrelandPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Cervical Cancer1 trial
Safety and Feasibility of TA-CIN Vaccine in HPV16 Associated Cervical Cancer
Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT02405221·15 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TA-CIN. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details